PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Rype addresses the dilemma of choosing between expensive or low-quality office furniture that contributes to carbon emissions and waste. By remanufacturing high-quality used office furniture, Rype offers cost-effective solutions with 80% lower carbon emissions and waste, while creating local jobs. Their mission is to significantly reduce office carbon emissions and costs through sustainable, circular economy practices, including exclusive furniture ranges made from waste materials. Rype's comprehensive services encompass furniture sourcing, remanufacturing, and employing marginalized individuals, contributing to a more environmentally friendly and socially responsible approach to office furnishings.
days to go:
Extended
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
GoPower offers comprehensive portable solar energy solutions, designed to save you money and reduce your environmental impact. Their user-friendly solar panels eliminate the need for complex installations, allowing easy setup anywhere. Their portable solar power stations, providing up to 1000w/1280WH at 240v, are perfect for various applications such as home offices, garden rooms, boats, events, and more. With multiple output sockets and versatile charging options including solar panels and mains electricity, GoPower provides a greener and cost-effective energy alternative.
days to go:
Extended
investment:
£10,000
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go:
Expired
investment:
£81,720
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.
days to go:
Expired
investment:
£49,990
Bua Fit is easy to use, a simple way to book web application for outdoor fitness classes. It eliminates all the trouble by connecting the trainers to clients for group fitness classes and gives the customers a diversity of trainers. The company has been a finalist in The Great British Entrepreneurial Challenge, has a network of 100 trainers and 42% active user rate since launch. With the proceeds, the company will earn more users, more trainers, more revenue, invest in product development and expand the team.
days to go:
Expired
investment:
£205,378
FLY LDN is a fitness brand that imparts sports and fitness instruction via its digital platform and its studios in central London and Fitzrovia. The company launched its video-on-demand and live-streaming fitness platform, FLY LDN Online (FLO), in September 2020. It asserts that within six months of launch, FLO scaled over 28,000 monthly views across 80+ countries with users having viewed over 2.5 million minutes of FLY LDN workouts. FLY LDN won the Men's Health 'Best Studio 2019' award and was commended at the 2018 and 2019 Tatler Gym Awards. The company has also received press coverage in publications like Women's Health, Forbes, Esquire, Elle, Vogue, GQ and Glamour. It has also partnered with brands such as DKNY and ASOS. FLY LDN aspires to become a contender in the global online fitness market that is expected to reach $59 billion by 2027. The company will use the investment to further develop additional functionality and TV apps for FLO and fund marketing campaigns to fuel growth.
days to go:
Expired
investment:
£340,928
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
